/VICP
VICP Stock - Vicapsys Life Sciences, Inc.
Healthcare|BiotechnologyOTC
$1.50+0.00%
+$0.00 (+0.00%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.28
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.65
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VICP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.48 – $1.52
TARGET (TP)$1.72
STOP LOSS$1.38
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-4.13
52W High$7.00
52W Low$1.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | $-31,288 | $-31,329 | $-31,424 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-813,836 | $-1,046,978 | $-984,790 | $-336,871 | $-765,844 |
| Net Income | $-989,798 | $-1,182,112 | $-984,790 | $-236,871 | $-765,844 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.03 | $-0.03 | $-0.03 | $-0.01 | $-0.04 |
Company Overview
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN proprietary product. Its product is applied to transplantation therapies and related stem-cell applications in the transplantation field. The company is also developing VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
VICPBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q1 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q4 24
No data
Q1 25
No data
Q1 25
No data
Q1 25
No data
Q1 25
No data
Q1 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2025 | Mar 31, 2025 | — | $-0.01 | — | — |
Q1 2025 | Jan 10, 2025 | — | $-0.01 | — | — |
Q1 2025 | Jan 10, 2025 | — | $-0.01 | — | — |
Q1 2025 | Jan 10, 2025 | — | $-0.01 | — | — |
Q1 2025 | Jan 10, 2025 | — | $-0.01 | — | — |
Q4 2024 | Oct 21, 2024 | — | $-0.01 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-0.01 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-0.00 | — | — |
Q2 2023 | May 15, 2023 | — | $-0.01 | — | — |
Q2 2023 | Apr 14, 2023 | — | $-0.03 | — | — |
Q4 2022 | Nov 21, 2022 | — | $-0.00 | — | — |
Q3 2022 | Aug 16, 2022 | — | $-0.01 | — | — |
Q2 2022 | May 13, 2022 | — | $-0.01 | — | — |
Q1 2022 | Mar 16, 2022 | — | $-0.01 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-0.01 | — | — |
Q3 2021 | Sep 20, 2021 | — | $0.00 | — | — |
Q3 2021 | Sep 20, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 17, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 13, 2021 | — | $-0.01 | — | — |
Q3 2021 | Sep 9, 2021 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about VICP
What is VICP's current stock price?
Vicapsys Life Sciences, Inc. (VICP) is currently trading at $1.50 per share. The stock has moved +0.00% today.
What is the analyst price target for VICP?
No analyst price targets are currently available for this stock.
What sector is Vicapsys Life Sciences, Inc. in?
Vicapsys Life Sciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is VICP's market cap?
Vicapsys Life Sciences, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does VICP pay dividends?
No, Vicapsys Life Sciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHFF
Arch Biopartners Inc.
$0.89
Mkt Cap: $0.1B
CLTEF
Calliditas Therapeutics AB (publ)
$0.55
Mkt Cap: $0.0B
HBPCF
Helix BioPharma Corp.
$1.73
Mkt Cap: $0.1B
INNMF
Amplia Therapeutics Limited
$0.08
Mkt Cap: $0.0B
OTLC
Oncotelic Therapeutics, Inc.
$0.09
Mkt Cap: $0.0B
PSYBF
PsyBio Therapeutics Corp.
$0.00
Mkt Cap: $0.0B
RLFTF
Relief Therapeutics Holding AG
$2.70
Mkt Cap: $0.0B
RLFTY
MindMaze Therapeutics Holding S.A. Sponsored ADR
$3.65
Mkt Cap: $0.0B
SNANF
Sona Nanotech Inc.
$0.35
Mkt Cap: $0.0B
ZIVO
ZIVO Bioscience, Inc.
$9.98
Mkt Cap: $0.0B
Explore stocks similar to VICP for comparison